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ABSTRACT
Coronary artery disease (CAD) predominantly manifests in older population above the age of 60 years old. The incidence 
of CAD in younger individuals has been reported and is called premature CAD (pCAD). The prevalence for pCAD in 
individuals below 45 years old is about 3-10% worldwide. Advances in risk prediction are of great importance as 
absolute values of risk factors sometimes correlate poorly with individuals. The measurement of traditional risk factors 
such as cholesterol level and blood pressure might be inadequate to predict risk for pCAD and therefore new biomarkers 
are required. The introduction of omics technology offers insight into the mechanism and interactions involved during 
disease progression and open the possibilities of discovering new biomarkers. Currently, new potential biomarkers for 
pCAD have been explored such as homocysteine, apolipoproteins, microRNAs and single nucleotide polymorphisms. In 
this review, we discussed the associated risk factors for pCAD, several reported and newly proposed biomarkers and 
their potential to be used clinically.
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ABSTRAK
Penyakit arteri koronari (CAD) sering berlaku dalam populasi yang berumur 60 tahun ke atas. Walau bagaimanapun, 
kejadian dalam individu muda yang dipanggil CAD pramatang (pCAD) telah dilaporkan. Prevalens pCAD bagi individu 
di bawah umur 45 tahun adalah 3-10% di seluruh dunia. Kemajuan dalam meramal risiko adalah penting kerana nilai 
faktor risiko mutlak kadangkala berkorelasi lemah dengan individu. Pengukuran faktor risiko tradisi seperti paras 
kolesterol dan tekanan darah mungkin tidak mencukupi untuk meramal risiko pCAD, oleh itu penanda biologi baru 
diperlukan. Pengenalan teknologi omik memberikan lebih kefahaman terhadap mekanisme dan interaksi yang berlaku 
sewaktu perkembangan penyakit dan membuka kemungkinan untuk penemuan penanda biologi baru. Ketika ini, penanda 
biologi pCAD yang baru telah diteroka seperti homosisteina, apolipoprotein, mikroRNA dan polimorfisma nukleotida 
tunggal. Dalam ulasan ini, kami membincangkan tentang faktor risiko pCAD yang berkaitan, beberapa penanda biologi 
yang dilaporkan dan yang baru dicadangkan dan potensi mereka untuk digunakan secara klinikal. 
Kata kunci: Aterosklerosis; penanda biologi; penyakit koronari arteri pramatang
INTRODUCTION
Coronary artery disease (CAD) remains one of the leading 
causes of death in the world, despite a decrease in mortality 
and morbidity rates in the past decade (Nichols et al. 
2014). CAD is commonly found among older individuals, 
while the prevalence among the younger population 
varies between 3 and 10% (Mohan et al. 2001; Wilson 
et al. 1998). In America, the predisposition risk of 
cardiovascular disease in men between 30-34 years old is 
3% and the risk increased to 21% when they reach 60-64 
years old (Wilson et al. 1998). In Japan, the prevalence 
is 1.26 cases for every 1000 patients below 50 years 
old (Satoh et al. 2006) while in India, the prevalence 
recorded is about 10% (Mohan et al. 2001). Another 
study reported that, only a small percentage (<10%) of all 
patients with myocardial infarction are among individuals 
below 45 years old (Morillas et al. 2007). In Malaysia, 
24% of 16,872 ACS patients that have been admitted to 
17 hospitals in Malaysia between 2006 and 2010 were 
below 50 years old. 33% of them were active smokers, 
33% were diagnosed with dyslipidemeia, 61% were 
hypertension, 41% were diabetic and 11% have family 
history with premature CAD (pCAD) (Wan Ahmad & Sim 
2013). Compared to other country databases, Malaysian 
who undergone percutaneous coronary intervention (PCI) 
were much younger and have higher prevalence for risk 
factors (Ahmad et al. 2013). Although most studies suggest 
a low incidence rate for pCAD, it is possible that the exact 
number of young individuals with atherosclerosis is 
probably much larger than currently estimated. In addition, 
the rise in cardiovascular risk factors such as smoking 
and obesity among younger population could lead to an 
increase in pCAD cases (Arzamendi et al. 2011). Therefore 
early detection and treatment of subclinical CAD and the 
prevention of developing acute coronary events should be 
emphasized among young adults.
 Predicting risk and disease development is challenging 
and cardiovascular disease is no exception. Absolute values 
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of risk factors such as cholesterol level sometimes correlate 
poorly within individuals (Castelli 1996). Accurately 
determining the risk among the younger population is 
paramount if prevention strategies were to be targeted 
appropriately. Current understanding on pathobiology of 
atherosclerosis has linked inflammation (Libby 2012) and 
oxidative stress (Madamanchi et al. 2005) as the central 
contributors to the initiation and progression of coronary 
artery disease. Identifying associated markers that may 
have prognostic values for future cardiovascular events in 
high risk patients may be crucial. Importantly, it will be 
useful in predicting diseases among individuals with no 
apparent syndrome or in younger populations who tend 
to develop CAD earlier in life. This could improve early 
diagnosis and enhance prevention strategies. In this review, 
we discussed on the associated risk factors, biomarkers 
as well as novel approaches that has been proposed in the 
literature focusing on pCAD.
RISK FACTORS ASSOCIATED WITH PCAD
A number of variables has been suggested to be predictive 
of cardiovascular events and such variables qualify as 
risk factors for CAD. Risk factors can be categorized into 
two different groups - modifiable and non-modifiable. 
Modifiable risk factors such as smoking, cholesterol levels, 
blood pressure and diabetes mellitus can be controlled by 
lifestyle interventions while non-modifiable risk factors 
such as age, gender and family history are factors that 
cannot be altered (Table 1). 
infarction remains highest in men, women appeared to 
exhibit the worst prognosis (Milcent et al. 2007).  Young 
women showed a greater post-infarction mortality in 
hospital and up to 1-year after discharge in comparison to 
men (4.23% vs. 2.21%, p = 0.005) (Egiziano et al. 2013).
A study on gender related risk factors showed that women 
have significantly higher frequency of diabetes, family 
history of CAD and hypertension. In addition, women with 
a positive family history showed the greatest risk factor 
burden including traditional risk factors of hypertension 
(67%), obesity (53%), dyslipidemia (67%), smoking 
(42%) and diabetes (33%) and non-traditional risk factors 
of depression (37%), anxiety (55%) and low household 
income (44%) (Choi et al. 2014). While women have 
higher rates of hypertension and diabetes, their background 
were seen less among the smokers (Shehab et al. 2013). 
Although the prevalence for smoking among women 
is lower, it has been shown to give a greater effect on 
women with 60 percent increased risk for coronary heart 
disease (CHD) as compared to men who smoke (Prescott 
et al. 1998).
FAMILY HISTORY WITH CAD
Family history of CAD has been established as an 
independent risk factor for CAD from multiple populations 
based studies. It is estimated that heredity contributes 
to at least 50% of susceptibility to CAD. Importantly, 
the strength of risk is higher with younger age of onset 
(Sesso et al. 2001). In a survey of 15,381 patients, the 
frequency of young patients having family history of CAD 
(43.6%) is significantly higher compared to late onset CAD 
(26.5%) (Reibis et al. 2012) supporting the contribution 
of heredity to the occurrence of pCAD. A subsequent study 
from CONFIRM Registry involving 6308 young patients 
has reported that those with a family history of CAD have 
higher prevalence of pCAD. After a follow-up period, 
patients with family history of CAD also experienced higher 
annual rates of myocardial infarction (Otaki et al. 2013). A 
similar observation is recorded in Framingham Offspring 
Study as parental cardiovascular disease has been found 
to independently predict future events in middle age 
offspring. Among 2302 subjects (mean age = 44 years), 
164 men and 79 women had cardiovascular events during 
follow-up. Those who have at least one parent with pCAD 
had higher risk for events, with OR=2.6 (95% CI, 1.7-4.1) 
for men and 2.3 (95% CI, 1.3-4.3) for women after adjusted 
with age compared to control (Lloyd-Jones et al. 2004).
 In asymptomatic first degree relative of patients with 
pCAD, the frequency of abnormal calcium scores is two-
fold higher compared to control with OR=1.96 (95% CI 1.04 
– 3.67, p<0.05) (Taraboanta et al. 2012). A non-premature 
parental coronary disease appears to be a weaker predictor 
(Lloyd-Jones et al. 2004). The risk frequency differs 
according to the population studied implying a genetic 
determinant or race-specific association for the disease. 
Multi ethnic comparison involving 13,591 patients from 
3 ethnic groups (Malay, Chinese and Indian) in Malaysia 
TABLE 1. Associated risk factors for CAD and pCAD
CAD risk factors
Non-modifiable Modifiable
Age
Sex
Race
Family history
Smoking status
Blood pressure
Diabetes Mellitus
Cholesterol levels
Physical activity
Obesity
GENDER
It is well-acknowledged that pCAD is highly associated 
with males. Several studies have reported differences 
in baseline characteristics and clinical presentations 
between men and women. For instance, women with acute 
coronary syndrome (ACS) in the Canadian population are 
significantly older and are more likely to have diabetes, 
hypertension and a history of heart failure (Poon et al. 
2012). Studies from PROSPECT, AMIS PLUS Registry and 
Gulf RACE-2 have recorded similar findings (Lansky et al. 
2012; Radovanovic et al. 2007; Shehab et al. 2013). It was 
also reported that women were more frequently to have 
normal or mild disease when presented to angiogram (Dey 
et al. 2009). Although the incidence of acute myocardial 
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revealed that the Indians have the highest frequency 
of family history of pCAD suggesting a strong genetic 
predisposition to CAD in this ethnic group (Lu & Nordin 
2013). White middle age group with any parental history of 
premature CVD (pCVD) also appear to have higher odds of 
coronary artery calcium than those with no parental history 
(OR= 1.55, 95% CI 1.01-2.37). Significant association has 
also been observed between parental pCVD with intima 
media thickness in Caucasians with paternal pCVD (OR= 
1.93, 95% CI 1.10-3.39) or any parental pCVD (OR= 1.67, 
95% CI 1.02-2.74) while no association has been observed 
in black participants (Wilkins et al. 2014). 
SMOKING
Despite all efforts to reduce smoking on a global scale, 
smoking remains as one of the strongest risk factors 
for pCAD (Hbejan 2011; Hozawa et al. 2006). Previous 
research involving 200 patients below 35 years old who 
underwent coronary angiography reported that smoking 
(71%) is the most frequent risk factor in pCAD (Christus 
et al. 2011). Furthermore, the attributable proportions of 
CHD among women who smoke in 8 pooled cohort studies 
were highest in the young group with 88% for 40-49 years 
old, 81% for 50-59 years old, 71% for 60-69 years old and 
68% for above 70 years old. The hazard ratio of CHD in 
current smokers relative to non-smokers also appears to be 
highest in the youngest and lowest in the oldest group in 
both men and women (Tolstrup et al. 2014). The relative 
risk for CAD for patients included in the Framingham 
Heart Study is about three times higher among young 
smokers as compared to the non-smokers. Pathobiological 
Determinants of Atherosclerosis in Youth (PDAY) reported 
that smokers (32%) have over twice advanced lesions 
compared to the non-smokers (14%) (Zieske et al. 1999). 
Smokers also have greater prevalence of Grade 5 lesions 
compared to the non-smokers suggesting that smoking 
accelerates the transition from Grade 4 to Grade 5 lesions 
(Zieske et al. 2005). Although smoking cessation in young 
healthy smokers showed normalization of endothelial 
dysfunction, smoking effect is not reversible in middle-age 
adults (Naya et al. 2011). 
CHRONIC DISEASES
Diabetes, hypertension and hypercholesterolemia are also 
frequently present in early and late onset of CAD. These 
are considered as modifiable risk factors but involve both 
environmental as well as genetic components. Whereas the 
significant involvement of these factors in CAD progression 
is well documented, their importance amongst pCAD 
is still poorly described. Most studies on angiography 
profiles of CAD patients showed that older patients are 
more diabetic (Pineda et al. 2008; Uddin et al. 2004). 
However, the frequency of cardiovascular risk factors 
such as overweight and high cholesterol among young 
people with type 1 diabetes mellitus remained common 
(Dobrovolskienė et al. 2013). Similarly in Malaysia, the 
prevalence for hypertension was higher in people above 60 
years old (26.8%), while people between 40-49 years old 
have the highest prevalence for obesity (22.7%) (Yunus et 
al. 2004). Young hypertensive subjects with multiple risk 
factors including positive family history (OR= 12.317), 
low HDL (OR= 3.267) and hypertriglyceridemia (OR= 
2.894) are significantly associated with pCAD (Che et al. 
2013). Although hypercholesterolemia is a common risk in 
CAD, many researchers have reported a higher prevalence 
in younger group. The prevalence for this risk is about 
73% in young patients compared to 59% in older patients 
(Pineda et al. 2008).
PATHOGENESIS OF CAD
The mechanism underlying the pathogenesis of CAD is 
the formation of atherosclerotic plaque characterized 
by deposition of cholesterol into the arterial wall. These 
events usually occur at the site of damaged endothelium 
possibly due to oxidative stress, physical forces or shear 
stress from the blood flow (Cunningham & Gotlieb 2005). 
The pro-oxidant milieu in intima creates an oxidative stress 
environment and promotes LDL cholesterol oxidation. 
Oxidized LDL (oxLDL) can further damage endothelial 
cells and induce adhesion molecules expression such as 
P-selectin and trigger monocytes and leukocytes migration 
into the intima (Napoli et al. 1997). Endothelial cell, 
smooth muscle cells and macrophage then secretes growth 
factors and inflammatory cytokines (Ross 1993). In intima, 
monocytes differentiate into macrophage and internalize 
oxLDL via scavenger receptor SR-A and CD-36 (Kunjathoor 
et al. 2002). This process eventually leads to foam cells 
formation and stimulate smooth muscle cells to proliferate 
and form a cap on top of the plaque. In some cases, plaques 
become unstable due to degradation of collagen by matrix 
metalloproteinase (MMPs) and prone to rupture (Lin et al. 
2014) resulting in formation of thrombus (Figure 1). 
 Atherosclerotic plaque development involves the 
interaction between many genes and the environment. 
Potential genes that attribute to the heritability component 
include several mutations that mostly affect HDL and LDL 
cholesterol levels such as LDLR, ApoB, ApoA1 and ABCA1 
(Watkins & Farrall 2006). Moreover, understanding the 
role of proteins that are important in inflammatory reaction 
such as VCAM-1, ICAM-1, IL-6 and MCP-1 and regulatory 
process such as NF- κB, TNF-α and IFN-γ, are essential 
as these genes and proteins have potential to become 
biomarkers for pCAD. Assessment of their function needs to 
be done carefully as some of them are capable of executing 
multiple actions (Ozaki & Leonard 2002).
POTENTIAL BIOMARKERS FOR PCAD
Recently, the American College of Cardiology and the 
American Heart Association (ACC/AHA) has proposed a 
guideline for risk assessment for CAD (Goff et al. 2014). 
However, the recommendations did not emphasize on pCAD 
and only provide a rough estimation for individual risk. 
A number of studies also have proposed different types 
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of biomarkers for CAD (Siemelink & Zeller 2014; Yayan 
2013) while the importance of finding indicators for pCAD 
are fairly neglected. As some studies provide evidence 
that there are differences exist in the plaque morphology 
between younger and older CAD patients (Ruiz-Garcia et 
al. 2012), it is possible that current proposed biomarkers 
for CAD are not applicable for pCAD. Therefore there is 
an urgent need for studies that include risk assessment 
for young individuals and to develop biomarkers that are 
specific for this population.
HOMOCYSTEINE
An elevated serum concentration of homocysteine 
(a state called hyperhomocysteinemia) is a known 
risk factor for atherosclerosis and associated with an 
increased risk of myocardial infarction and mortality. An 
epidemiological study suggested a positive association 
between homocysteine (Hcy) concentrations and risk for 
cardiovascular disease (Graham et al. 1997). Previous 
data have shown that elevated homocysteine levels can be 
detected in 30% of CAD patients. The mechanisms involved 
by which homocysteine impairs vascular function is only 
partially understood. High homocysteine is involved in 
several potential mechanisms resulting in a decrease in the 
availability of endothelial cell-derived NO, impairment of 
endothelial function, an increment in monocyte adhesion 
(Faraci 2003),  induction of oxidative stress, and increased 
tendency for thrombosis (Kaul et al. 2006). Although most 
available data support the involvement of homocysteine in 
CAD, most intervention studies which involved lowering 
homocysteine levels failed to reduce clinical events (Albert 
et al. 2008, Armitage et al. 2010).
 The association of homocysteine with atherosclerosis 
in both case control observations and prospective cohort 
studies has been reported for pCAD. A case control study 
among male and female patients aged below 45 years with 
CAD showed hyperhomocysteinemia as an independent 
risk factor for pCAD where the risk is higher in men (OR= 
2.54, 95% CI, 1.23-5.22, p = 0.01). Hyperhomocysteinemia 
is shown to be significantly influenced by vitamin B12 
deficiency (Sadeghian et al. 2006). A more recent study 
reported higher plasma homocysteine level in cases 
compared to healthy controls (22.14 ± 10.62 μmol/l vs 
17.38 ± 8.46 μmol/l) with OR= 1.93 (95% CI, 1.27-2.94) 
(Gupta et al. 2012). Homocysteine levels also appear to be 
higher in multiple vessel disease. The mean homocysteine 
levels are 12.6 and 15.5 μmol/L in patients with single 
and  multi-vessel CAD respectively (Eftychiou et al. 
2012). However, several studies reported contradicting 
findings. A cross sectional study showed neither high 
homocysteine nor lipoprotein (a) is associated with CAD in 
young women. However, a strong association with disease 
is found when both risk factors are present (OR=4.83, 
p=0.003). Homocysteine level and lipoprotein (a) are 
also independent risk factors for CAD in young men. The 
presence of both risk factors did not confer additional risk 
to the development of pCAD (Foody et al. 2000).
APOLIPOPROTEIN
The metabolism of apolipoprotein is closely associated 
with the development of atherosclerosis.  In particular, 
apoA1 is the main component in high density lipoprotein 
(HDL) involved in reverse cholesterol transport (Yancey 
et al. 2003), whereas ApoE is a protein that mediates 
the transport and uptake of cholesterol and lipid (Saito 
et al. 2004). Furthermore, ApoB is a protein constituent 
of the atherogenic very low density lipoproteins (VLDL), 
intermediate density lipoproteins (IDL) and LDL (Ray et al. 
2009). Measurement of plasma apolipoprotein allows an 
assessment of the total atherogenic and anti-atherogenic 
particles in the circulatory system.
FIGURE 1. Mechanism of atherogenesis. Endothelial dysfunction promotes migration of LDL particle into the sub-endothelial space 
where they are subjected to oxidation by reactive oxygen species. Oxidized LDL further trigger endothelial cells to express adhesion 
molecules including VCAM-1 and ICAM-1 and promote monocytes migration. In the sub-endothelial space, macrophages internalize 
oxidized LDL and form foam cells. This process involves multiple components including pro-inflammatory cytokines such as IL-6 and 
TNF-α produced by endothelial cells, macrophages and foam cells. Pro-inflammatory cytokines induce smooth muscle cells migration 
and form a cap on top of the plaque. In some cases, the plaque become unstable and prone to rupture and leads to thrombus formation
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 Patients with high ApoB and small density LDL have 
been reported to have three-fold increased risk of pCAD (St-
Pierre et al. 2005). In genetic dyslipidemia, reduced ApoA1 
levels and elevated ApoB levels predict pCAD (Ayyobi 
et al. 2007). A study of 203 pCAD patients examined the 
association between ApoB and ApoA1 with pCAD. ApoA1 
is found to be independently associated with pCAD in 
men and plasma ApoB level is the strongest independent 
variable associated with pCAD in women (Kwiterovich et 
al. 1992). A similar finding was also reported involving 
243 men and 61 women with pCAD and 203 age and 
sex-match controls. ApoB level has been found to be a 
predictor of risk in women (Weber et al. 1997). A study in 
non-diabetic pCAD patients showed that ApoB is a better 
marker than traditional lipids where ApoB concentrations 
is significantly higher in CAD group compared to normal 
(102 ± 24 versus 84 ± 17, p< 0.001) (Azizi et al. 2002). 
Therefore, measurement of ApoAI and ApoB levels may 
improve our ability to evaluate pCAD risk beyond lipid 
measurement.
FIBRINOGEN AND FIBRIN
Fibrinogen is the precursor of fibrin and considered to 
be a determinant for atherogenesis (Herrick et al. 1999). 
Multiple studies showed significant associations between 
CHD as well as cardiovascular disease (CVD) (Okwuosa 
et al. 2013). Fibrinogen circulates in the plasma and 
the normal concentration is 200-400 mg/dL. However, 
fibrinogen levels can decline with lifestyle modifications 
such as exercise (Ernst 1993) and smoking cessation 
(Hunter et al. 2001). In young adults, fibrinogen also 
showed a positive association with most risk factors for 
cardiovascular disease. Fibrinogen level is positively 
associated with body mass index, cigarette smoking, 
LDL cholesterol, blood pressure and triglycerides while 
negatively associated with HDL cholesterol, alcohol intake 
and physical activity (Folsom et al. 1993). 
 The role of fibrin in pCAD was examined in a group 
of young, post myocardial infarction patients with 
angiographic proven CAD and in healthy volunteers 
matched for age and sex. Young CAD patients had 
significantly higher plasma fibrinogen, plasminogen 
activator inhibitor type I, von Willbrand factor and 
lipoprotein (a) as compared to controls. Fibrin of young 
patients was made of numerous and shorter fibres, stiffer 
and lysed at a slower rate than controls. Fibrin stiffness 
was found to be an independent predictor for both 
hypofibrinolysis and pCAD (Collet et al. 2006). High 
plasma fibrinogen also predicts critical coronary lesions in 
pCAD (Tatli et al. 2009). A case-control study conducted to 
discover the association between fibrinogen and premature 
myocardial infarction in middle age men less than 55 
years old showed an elevated level of plasma fibrinogen 
in patients (354.9 ± 60 mg/dL) compared to the control 
group (329 ± 73 mg/dL). Hyperfibrinogenemia was found 
in 81.8% of the patients and 57.5% of controls (OR= 3.3, 
p= 0.036) (Shojaie et al. 2009). Essentially, in first degree 
relatives of patients with pCAD, a significant increase in 
fibrinogen levels has been demonstrated. These findings 
highlighted the importance of screening fibrinogen in 
healthy individuals who other than their family history, 
appeared to be at low risk in terms of conventional CAD 
risk factors (Mills et al. 2002).
GAMMA GLUTAMYL TRANSFERASE (GGT)
GGT is an enzyme present in the serum and on the outer 
surface of cells. It is responsible for the synthesis of 
extracellular glutathione (Shabbir et al. 2011). GGT 
levels are examined for liver and gallbladder diagnosis, 
especially for alcoholic related disease. Recent evidence 
suggests that  increased serum gamma glutamyl transferase 
(GGT) is associated with cardiovascular disease (Mao et 
al. 2014). A number of epidemiological studies partly 
explained the correlation of GGT with multiple risk factors 
including obesity, hypertension, diabetes and metabolic 
syndrome suggesting it might participate in oxidative and 
inflammatory reactions (Lee et al. 2003; Nakanishi et al. 
2004; Onat et al. 2012). Relationship between GGT activity 
and cardiovascular incidents had also been shown to be 
independent of alcohol intake in a meta-analysis (Fraser 
et al. 2007). However, the exact mechanism that relates 
GGT and cardiovascular disease is still unclear. Several 
hypotheses have been proposed including GGT itself is 
pro-atherogenic (Emdin et al. 2005) and elevated  GGT is 
a marker for metabolic syndrome (Lee et al. 2007).
 In established CAD patients, GGT is independently 
associated with increased arterial stiffness in both men 
and women (Zhu et al. 2013). Moreover, the increased 
GGT activity is related to clinical stability, LV function 
and inflammatory activity rather than the CAD severity 
(Demircan et al. 2009). Shabbir et al. (2011) reported the 
association of GGT activity with pCAD in young Pakistani 
patients (age < 45 years old) who went for angiography. 
Their results showed that GGT activity was positively 
correlated with higher blood pressure, glucose, smoking 
and cholesterol and negatively correlated with antioxidant 
status. Furthermore, GGT activity increased significantly 
in pCAD compared to controls. Their findings suggest a 
good diagnostic accuracy at cut-off of 35 U/L, with 81% 
specificity, 92% sensitivity and diagnostic odds ratio of 48 
for prediction of pCAD in young Pakistanis.
SYMMETRIC AND ASSYMETRICDIMETHYLARGININE     
(SDMA AND ADMA)
Assymetricdimethylarginine (ADMA) is an endogenous 
inhibitor for nitric oxide synthase and regulates the rate 
of NO production (Leiper & Vallance 1999). ADMA has 
been regarded as a potential biomarker for cardiovascular 
disease and may potentially influence restenosis after 
angioplasty (Derkacz et al. 2011). Moreover, among 
young healthy subjects, ADMA has been suggested to have 
a role in regulating systemic vascular tone (Paiva et al. 
2008). Studies on ADMA associated risk in smokers and 
non-smokers showed an adjusted relative risk for future 
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coronary events of 2.40 (95% CI 1.14-5.08; p=0.021) 
in non-smokers and 0.48 (95% CI 0.16-1.46; p=0.198) 
in smokers. It was suggested that ADMA metabolism 
may be altered by tobacco smoke (Maas et al. 2007). A 
follow-up study involving 1148 coronary heart disease 
patients showed ADMA is not associated with secondary 
CVD events. After 8 years, 150 patients had a secondary 
event and 121 patients died and an association was only 
suggested for symmetricdimethylarginine (SDMA) (HR 
1.17 [1.00–1.37]) (Siegerink et al. 2013). SDMA levels 
also have been shown to be independently associated 
with increased cardiovascular and all-cause mortality in 
subjects undergoing coronary angiography (Meinitzer et 
al. 2011). The differences in terms of the risk pattern in 
SDMA and ADMA suggest both methylarginines have unique 
pathophysiological roles in CAD.
 A study on a population of young Indians (age between 
15 and 50 years) showed plasma ADMA concentrations in 
patients with ischemic stroke were significantly higher 
compared to age matched controls (1.49 vs. 0.97 μmol/l, 
p<0.001). The association with stroke remained significant 
even after adjustment with cardiovascular risk factors 
(OR=1.55, 95% CI 1.25–1.92, p<0.001)(Mamatha et al. 
2011). In another study on young Egyptians (age between 
35 and 50 years old), only SDMA level is significantly 
elevated in patients. However, when comparing between 
chronic (patients who went for medical treatment, PCI or 
CABG) and acute (patients with acute myocardial infarction) 
patients, both ADMA and SDMA levels were significantly 
higher only in acute patients (Gad et al. 2010). 
GENETIC POLYMORPHISMS AS BIOMARKERS
The development of atherosclerosis involves both 
environmental and genetic factors. Beside traditional risk 
factors such as smoking, physical activity and dietary, 
clinical outcome can be influenced by genetic variants. 
Recent genome-wide association studies have reported 
35 common genetic variants associated with CAD in 
European population (Peden & Farrall 2011) which 
were replicated in Japan and Korean populations (Lee 
et al. 2013). Although the main contribution for these 
genome-wide scans is to identify possible mechanisms 
and pathways leading to the disease thus offering potential 
intervention, the usefulness of the SNPs as predictive 
biomarkers has been demonstrated in a few studies 
(Kathiresan et al. 2008; Ripatti et al. 2010). Several SNPs 
also showed significant association with pCAD providing 
further support of the potential of SNPs for pCAD (Table 2). 
 A previous study reported the association of 48 
coding and 3 non-coding SNPs from 35 inflammatory 
genes with CAD. Significant association was observed 
between three locus haplotype in interleukin 1 cluster 
with p=0.006 in all CAD cases, p=0.01 in myocardial 
infarction and p=0.0002 in pCAD (Brown et al. 2010). 
After adjusting for traditional risk factors including sex, 
smoking, hypertension and hypercholesterolemia, the 
haplotype effect remained significant in pCAD cases. A 
cross-sectional, observational study conducted in pCAD 
patients and controls with a mean age below 45 years to 
determine the effect of IL-10 gene promoter polymorphism 
showed no relationship between polymorphism and 
adverse angiographic and clinical outcome, but found a 
significant difference in IL-10 -592C/A allelic frequency 
(OR=2.00, 95% CI 0.9434-4.2579) between patients and 
match controls (Karaca et al. 2011). However, in contrast, 
Cardiovascular Risk in Young Finns Study reported an 
inverse association in arterial stiffness index (p=0.0034) 
and Young’s elastic modulus (p=0.0005) demonstrating 
discordance with the supposed anti-atherogenic properties 
of IL-10 (Heiskanen et al. 2010).
 Similarly, IL-6 polymorphisms also showed 
conflicting findings. A study of Pakistani families 
involving 36 patients with mean age of 46.4 ± 18.7 
showed IL-6 polymorphism at-174 was more prevalent 
in CAD cases compared to healthy controls. There was 
significant association between IL-6 polymorphism 
and CAD suggesting an association with an increased 
risk for the disease (Satti et al. 2013). In multi-ethnic 
comparison, the -174 IL-6 allele frequency was higher 
in young Indians (23%) compared to Black participants 
(2%) with p<0.0001 (OR = 0.05, 95% CI 0.018–0.14). 
A significant association with CAD has also been found 
among young Indian patients when compared to control. 
However, several studies found no association of IL-6 
with CAD (Ghazouani et al. 2011; Sekuri et al. 2007). 
Nevertheless, single nucleotide polymorphism may offer 
predictive value for predisposition to pCAD.
MICRO-RNA (MIRNA)
Small non coding RNAs (miRNA) are typically 20 to 26 
nucleotides long which function mainly in regulation of 
post-transcriptional gene expression. As such, miRNA 
plays multiple roles in preserving biological processes 
including cell proliferation, apoptosis and tumorigenesis 
(Cordes & Srivastava 2009). In recent years, interest has 
escalated on miRNA as a potential biomarker as well as a 
potential therapeutic approach for cardiovascular disease 
(De Rosa et al. 2014; Hagiwara et al. 2014; Olson 2014). 
Numerous studies have been conducted on circulating 
miRNA in either acute myocardial infarction or CAD (Table 
3). For instance, 11 miRNAs have been found significantly 
downregulated among CAD patients compared to healthy 
controls. Although medication used may alter the relative 
miRNA expression, these results have implications in the 
use of miRNA for identifying and managing individuals 
with CAD or at higher risk of developing disease (Weber 
et al. 2011).
 A case control study investigated the role of miRNA in 
pCAD by comparing relative expression levels of platelet 
miRNAs using microarrays (Sondermeijer et al. 2011). 
Six platelet miRNAs were significantly upregulated in 
pCAD (miR340, miR451, miR454, miR545:9.1. miR615-
5p and miR624) while one miRNA (miR1280) was 
downregulated compared to controls. Validation studies in 
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two different cohorts confirmed that miR340 and miR624 
were upregulated in pCAD. However the limitation of this 
study is that the differences in miRNA expression levels 
between patients and controls were very small. It is difficult 
to determine if both miRNAs can be used as independent 
biomarkers for pCAD. Taken together, miRNAs have the 
potential utility to be novel biomarkers in CAD particularly 
in younger adults. However, further studies conducted 
using larger cohorts are necessary to evaluate and prove 
their candidacy as predictors for pCAD.
CONCLUSION
Understanding the mechanism of atherogenesis including 
lipid metabolism, endothelial dysfunction, oxidative stress 
and inflammation may be crucial if prevention strategies 
are to be targeted accurately. The usual risk factors of 
age, sex, family history, cholesterol level, smoking status, 
blood pressure and diabetes may be insufficient to predict 
risk to pCAD. The emergence of omics technology offer 
extensive information on the genes and proteins involved 
during disease progression and as such, can be potential 
biomarkers for CAD. As protein markers give an insight on 
the actual body condition, genetic markers might be a better 
marker for risk assessment. Knowledge at the genome 
level such as polymorphism can enhance our ability to 
identify high risk individuals as genomic data provide the 
information on susceptibility to disease particularly pCAD. 
A well-designed clinical trial should be conducted in order 
to properly validate their candidacy and maximize their 
potential as biomarkers.
 A good biomarker should be highly sensitive and 
specific to be used clinically. Although many biomarkers 
for CAD such as homocysteine, IL-6 or ApoB/ApoA1 ratio 
have been proposed, none are routinely used in diagnostic 
procedure except for CRP. Perhaps one of the reasons 
is because of evidence insufficiency from prospective 
cohort studies. As CAD is a complex disease that involves 
multiple stages and interactions, relying on one biomarker 
might be inadequate. The ideal alternative is to introduce a 
panel of biomarkers that provide a risk score or algorithm 
and evaluate the predisposition to pCAD so that early 
preventive measures and lifestyle modifications can be 
done. Nevertheless, recent data on potential biomarkers 
for pCAD can provide the basis for studies to further justify 
their prognostic value. Future studies should take the next 
step for risk prediction including in the determination of 
their role during disease progression as well as establishing 
markers to be used routinely.
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